Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.
Last trade$2.61
Day change-$0.05 (-1.88%)
Day range$2.45 – $2.83
Volume4,871
Market cap$31M
OpenXASE
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for NSRX.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for NSRX.
Recent news
Company coverage with links to the original publishers.
Nasus Pharma Ltd. (NYSE: NSRX) announced the appointment of Brendan P. O'Grady as Chief Executive Officer, effective July 27, 2026. O'Grady, a pharmaceutical industry veteran with 35 years of experience and former CEO of Teva USA, will lead the company's growth strategy with focus on commercializing NS002, an intranasal epinephrine treatment for anaphylaxis targeting a $2 billion market opportunity. He succeeds Dan Teleman in the leadership transition.
Virtual Investor Conferences announced that presentations from the June 24-25 Life Sciences Virtual Investor Forum are now available for on-demand viewing for 90 days. Twenty companies across the life sciences sector presented at the forum, with select companies still accepting 1x1 management meeting requests through June 19th.
Nasus Pharma reported positive Phase 2 results for NS002, its intranasal epinephrine powder, demonstrating statistically significant improvements in absorption speed compared to EpiPen®. The company plans to initiate a pivotal study in Q4 2026 and is advancing pipeline candidates NS003, NS004, and NS005 toward first-in-human studies in H2 2026. With $4.3 million in cash as of December 31, 2025, plus a $15 million private placement closed in February 2026, the company is well-funded through Q2 2027.
Nasus Pharma Ltd. (NYSE: NSRX), a clinical-stage pharmaceutical company developing intranasal products, announced that CEO Dan Teleman will present at three upcoming investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference (Feb 25), BIO Investment & Growth Summit (Mar 2), and Citizens Life Sciences Conference (Mar 3). The company is focused on developing NS002, an intranasal powder Epinephrine product as a needle-free alternative to autoinjectors for anaphylaxis treatment.
Nasus Pharma Ltd. (NYSE: NSRX) announced the closing of a private placement raising approximately $15.0 million gross proceeds through the sale of 2,695,425 ordinary shares and accompanying warrants at $5.565 per share. The company plans to use the proceeds to advance its NS002 intranasal epinephrine powder product candidate toward a pivotal study and NDA submission, while expanding its pipeline of intranasal powder-based programs.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.